全文获取类型
收费全文 | 166100篇 |
免费 | 13783篇 |
国内免费 | 5031篇 |
专业分类
耳鼻咽喉 | 1175篇 |
儿科学 | 3255篇 |
妇产科学 | 1726篇 |
基础医学 | 24426篇 |
口腔科学 | 3215篇 |
临床医学 | 16834篇 |
内科学 | 23642篇 |
皮肤病学 | 1759篇 |
神经病学 | 8001篇 |
特种医学 | 3984篇 |
外国民族医学 | 24篇 |
外科学 | 14021篇 |
综合类 | 25297篇 |
现状与发展 | 11篇 |
一般理论 | 25篇 |
预防医学 | 12233篇 |
眼科学 | 4591篇 |
药学 | 17484篇 |
15篇 | |
中国医学 | 8093篇 |
肿瘤学 | 15103篇 |
出版年
2024年 | 129篇 |
2023年 | 2346篇 |
2022年 | 3439篇 |
2021年 | 6348篇 |
2020年 | 5773篇 |
2019年 | 6253篇 |
2018年 | 5988篇 |
2017年 | 5477篇 |
2016年 | 5324篇 |
2015年 | 5396篇 |
2014年 | 8881篇 |
2013年 | 9607篇 |
2012年 | 7888篇 |
2011年 | 9143篇 |
2010年 | 7894篇 |
2009年 | 7773篇 |
2008年 | 7906篇 |
2007年 | 8936篇 |
2006年 | 8102篇 |
2005年 | 8073篇 |
2004年 | 7039篇 |
2003年 | 6244篇 |
2002年 | 4612篇 |
2001年 | 4525篇 |
2000年 | 3695篇 |
1999年 | 3395篇 |
1998年 | 2320篇 |
1997年 | 2071篇 |
1996年 | 2188篇 |
1995年 | 2195篇 |
1994年 | 1917篇 |
1993年 | 1754篇 |
1992年 | 1527篇 |
1991年 | 1314篇 |
1990年 | 1117篇 |
1989年 | 1049篇 |
1988年 | 992篇 |
1987年 | 747篇 |
1986年 | 570篇 |
1985年 | 684篇 |
1984年 | 710篇 |
1983年 | 438篇 |
1982年 | 542篇 |
1981年 | 456篇 |
1980年 | 404篇 |
1979年 | 335篇 |
1978年 | 270篇 |
1977年 | 225篇 |
1976年 | 248篇 |
1975年 | 156篇 |
排序方式: 共有10000条查询结果,搜索用时 125 毫秒
51.
Hannah C. Nordhues Anjali Bhagra Natya N. Stroud Jennifer A. Vencill Carol L. Kuhle 《Mayo Clinic proceedings. Mayo Clinic》2021,96(7):1907-1920
The coronavirus disease 2019 (COVID-19) pandemic has rapidly created widespread impacts on global health and the economy. Data suggest that women are less susceptible to severe illness. However, sex-disaggregated data are incomplete, leaving room for misinterpretation, and focusing only on biologic sex underestimates the gendered impact of the pandemic on women. This narrative review summarizes what is known about gender disparities during the COVID-19 pandemic and the economic, domestic, and health burdens along with overlapping vulnerabilities related to the pandemic. In addition, this review outlines recommended strategies that advocacy groups, community leaders, and policymakers should implement to mitigate the widening gender disparities related to COVID-19. 相似文献
52.
Kerstin Folkerts Natalia Petruski-Ivleva Erin Comerford Michael Blankenburg Thomas Evers Alain Gay Linda Fried Csaba P. Kovesdy 《Mayo Clinic proceedings. Mayo Clinic》2021,96(4):975-986
ObjectiveTo examine the screening rates for kidney damage and function among patients with type 2 diabetes (T2D) and chronic kidney disease stage at diabetes diagnosis using a US administrative claims database.Patients and MethodsThis cohort study used a claims database enriched with laboratory results data. Patients with T2D (defined as 1 inpatient or 2 outpatient claims for diabetes), aged 18 years or older, and with at least 1 year of follow-up enrollment were identified. Patients with type 1 diabetes, kidney disease, or other related conditions at baseline were excluded. We estimated screening rates using laboratory orders for serum creatinine and estimated glomerular filtration rate (eGFR) measurement and urine albumin to creatinine ratio (UACR). Chronic kidney disease severity was reported using the Kidney Disease: Improving Global Outcomes classification based on laboratory results.ResultsA total of 1,881,447 patients with T2D were eligible for analysis. Mean ± SD age was 63.1±13.1 years; 947,150 patients (50.3%) were male. Serum creatinine tests were ordered within 14 days of the index date among 290,722 patients of 622,915 (46.7%) patients with newly-recognized T2D. Overall, 1,595,964 patients (84.8%) had at least one serum creatinine test ordered during the 1-year follow-up period. Fewer patients received a UACR test during follow-up (814,897 [43.3%]). Less than half of all patients with T2D received a laboratory test order for both serum creatinine and urine albumin measurements during the follow-up period.ConclusionPhysicians treating patients with diabetes are selectively adhering to chronic kidney disease screening guidelines, as indicated by high rates of eGFR testing, but less frequent UACR testing. Despite recommendations to monitor both eGFR and UACR, less than half of patients were screened for albuminuria during the 1-year follow-up. 相似文献
53.
54.
55.
56.
Zongzhang Huang Qigu Yao Jianping Zhu Ying He Yanghao Chen Feng Wu Teng Hua 《Diagnostic and interventional imaging》2021,102(5):279-285
PurposeThe purpose of this study was to make a systematic review and meta-analysis to determine the stent diameter (8 mm vs. 10 mm) that conveys better safety and clinical efficacy for transjugular intrahepatic portosystemic shunt (TIPS).Materials and methodsFour databases were used to identify clinical trials published from inception until March 2020. Data were extracted to estimate and compare one-year and three-year overall survivals, hepatic encephalopathy, variceal rebleeding, and shunt dysfunction rates between patients with 8 mm covered stents and those with 10 mm covered stents.ResultsFive eligible studies were selected, which included 489 patients (316 men, 173 women). The 8 mm covered stent group had higher efficacy regarding one-year or three-year overall survival (odds ratio [OR], 2.88; P = 0.003) and (OR, 1.81; P = 0.04) and lower hepatic encephalopathy (OR, 0.69; P = 0.04) compared with 10 mm covered stent group. There were no significant differences in variceal rebleeding rate (OR 0.80; P = 0.67). However, shunt dysfunction was lower in 10 mm covered stent group (OR, 2.26; P = 0.003).ConclusionsOur results suggest that the use of 8 mm covered stents should be preferred to that of 10 mm covered stents for TIPS placement when portal pressure is frequently monitored. 相似文献
57.
58.
59.
60.